Anders Hove and Bong Koh‘s VHCP Management owns a new position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX), as a new filing with the US Securities and Exchange Commision showed. The 13G filing revealed that VHCP Management holds 5.24 million shares of BioCryst, which represent 7.1% of the company’s outstanding stock. The fund did not report holding shares in its last 13F filing. BioCryst Pharmaceuticals’ stock has lost more than 70% since the beginning of the year.
Follow Biocryst Pharmaceuticals Inc (NASDAQ:BCRX)
Follow Biocryst Pharmaceuticals Inc (NASDAQ:BCRX)
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
Overall, during the fourth quarter, the number of funds bullish on BioCryst among those we track inched up by one to 15. Among them, the largest stake was held by Julian and Felix Baker‘s Baker Bros. Advisors, followed by Peter Kolchinsky’s RA Capital Management, which reported stakes worth $146.7 million and $31.9 million, respectively, in their last 13F filings. Other peers with similar optimism consist of D. E. Shaw’s D E Shaw, Daniel Gold’s QVT Financial and Bihua Chen’s Cormorant Asset Management.
Moreover, it’s important to mention that several funds initiated stakes in BioCryst Pharmaceuticals in the last three months of 2015. Among them, Jim Simons’ Renaissance Technologies reported the largest new position, worth $1.5 million. Other funds with new holdings include Michael S. Weiss and Lindsay A. Rosenwald’s Opus Point Partners Management, David Costen Haley’s HBK Investments and Joel Greenblatt’s Gotham Asset Management.
You can access the original SEC filing by clicking here.
Ownership Summary Table
| Name | Sole Voting Power | Shared Voting Power | Sole Dispositive Power | Shared Dispositive Power | Aggregate Amount Owned Power | Percent of Class |
|---|---|---|---|---|---|---|
| Venrock Healthcare Capital Partners | 0 | 5,241,378 | 0 | 5,241,378 | 5,241,378 | 7.1% |
| VHCP Co-Investment Holdings | 0 | 5,241,378 | 0 | 5,241,378 | 5,241,378 | 7.1% |
| Venrock Healthcare Capital Partners II | 0 | 5,241,378 | 0 | 5,241,378 | 5,241,378 | 7.1% |
| VHCP Co-Investment Holdings II | 0 | 5,241,378 | 0 | 5,241,378 | 5,241,378 | 7.1% |
| VHCP Management | 0 | 5,241,378 | 0 | 5,241,378 | 5,241,378 | 7.1% |
| VHCP Management II | 0 | 5,241,378 | 0 | 5,241,378 | 5,241,378 | 7.1% |
| Hove, Anders | 0 | 5,241,378 | 0 | 5,241,378 | 5,241,378 | 7.1% |
| Koh, Bong | 0 | 5,241,378 | 0 | 5,241,378 | 5,241,378 | 7.1% |
Page 1 of 19 – SEC Filing
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. )*
BioCryst Pharmaceuticals, Inc.
(Name of Issuer)
Common Stock, $0.01 par value
(Title of Class of Securities)
09058V103
(CUSIP Number)
March 16, 2016
(Date of Event Which Requires Filing of This Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
¨ Rule 13d-1(b)
x Rule 13d-1(c)
¨ Rule 13d-1(d)
| * | The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. |
The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
Follow Biocryst Pharmaceuticals Inc (NASDAQ:BCRX)
Follow Biocryst Pharmaceuticals Inc (NASDAQ:BCRX)
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
Page 2 of 19 – SEC Filing
| CUSIP No. 09058V103 | Page 2 of 15 |
| 1. | Name of Reporting Persons Venrock Healthcare Capital Partners, L.P. | |||||
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions) (a) x1 (b) ¨ | |||||
| 3. | SEC USE ONLY | |||||
| 4. | Citizenship or Place of Organization Delaware | |||||
| Number of Shares Beneficially Owned by Each Reporting Person With: | | 5. | | Sole Voting Power 0 | ||
| | 6. | | Shared Voting Power 5,241,3782 | |||
| | 7. | | Sole Dispositive Power 0 | |||
| | 8. | | Shared Dispositive Power 5,241,3782 | |||
| 9. | Aggregate Amount Beneficially Owned by Each Reporting Person 5,241,3782 | |||||
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨ | |||||
| 11. | Percent of Class Represented by Amount in Row (9) 7.1%3 | |||||
| 12. | Type of Reporting Person (See Instructions) PN | |||||
| 1 | Venrock Healthcare Capital Partners, L.P., VHCP Co-Investment Holdings, LLC, Venrock Healthcare Capital Partners II, L.P., VHCP Co-Investment Holdings II, LLC, VHCP Management, LLC, VHCP Management II, LLC, Bong Koh and Anders Hove are members of a group for the purposes of this Schedule 13G. |
| 2 | Consists of 473,101 shares owned by Venrock Healthcare Capital Partners, L.P., 86,542 shares owned by VHCP Co-Investment Holdings, LLC, 3,331,104 shares owned by Venrock Healthcare Capital Partners II, L.P. and 1,350,631 shares owned by VHCP Co-Investment Holdings II, LLC. |
| 3 | This percentage is calculated based upon 73,629,816 shares of the Issuer’s common stock outstanding as of January 31, 2016, as set forth in the Issuer’s annual report on Form 10-K filed with the Securities and Exchange Commission on February 26, 2016. |
Follow Biocryst Pharmaceuticals Inc (NASDAQ:BCRX)
Follow Biocryst Pharmaceuticals Inc (NASDAQ:BCRX)
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
Page 3 of 19 – SEC Filing
| CUSIP No. 09058V103 | Page 3 of 15 |
| 1. | Name of Reporting Persons VHCP Co-Investment Holdings, LLC | |||||
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions) (a) x1 (b) ¨ | |||||
| 3. | SEC USE ONLY | |||||
| 4. | Citizenship or Place of Organization Delaware | |||||
| Number of Shares Beneficially Owned by Each Reporting Person With: | | 5. | | Sole Voting Power 0 | ||
| | 6. | | Shared Voting Power 5,241,3782 | |||
| | 7. | | Sole Dispositive Power 0 | |||
| | 8. | | Shared Dispositive Power 5,241,3782 | |||
| 9. | Aggregate Amount Beneficially Owned by Each Reporting Person 5,241,3782 | |||||
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨ | |||||
| 11. | Percent of Class Represented by Amount in Row (9) 7.1%3 | |||||
| 12. | Type of Reporting Person (See Instructions) OO | |||||
| 1 | Venrock Healthcare Capital Partners, L.P., VHCP Co-Investment Holdings, LLC, Venrock Healthcare Capital Partners II, L.P., VHCP Co-Investment Holdings II, LLC, VHCP Management, LLC, VHCP Management II, LLC, Bong Koh and Anders Hove are members of a group for the purposes of this Schedule 13G. |
| 2 | Consists of 473,101 shares owned by Venrock Healthcare Capital Partners, L.P., 86,542 shares owned by VHCP Co-Investment Holdings, LLC, 3,331,104 shares owned by Venrock Healthcare Capital Partners II, L.P. and 1,350,631 shares owned by VHCP Co-Investment Holdings II, LLC. |
| 3 | This percentage is calculated based upon 73,629,816 shares of the Issuer’s common stock outstanding as of January 31, 2016, as set forth in the Issuer’s annual report on Form 10-K filed with the Securities and Exchange Commission on February 26, 2016. |
Follow Biocryst Pharmaceuticals Inc (NASDAQ:BCRX)
Follow Biocryst Pharmaceuticals Inc (NASDAQ:BCRX)
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
Page 4 of 19 – SEC Filing
| CUSIP No. 09058V103 | Page 4 of 15 |
| 1. | Name of Reporting Persons Venrock Healthcare Capital Partners II, L.P. | |||||
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions) (a) x1 (b) ¨ | |||||
| 3. | SEC USE ONLY | |||||
| 4. | Citizenship or Place of Organization Delaware | |||||
| Number of Shares Beneficially Owned by Each Reporting Person With: | | 5. | | Sole Voting Power 0 | ||
| | 6. | | Shared Voting Power 5,241,3782 | |||
| | 7. | | Sole Dispositive Power 0 | |||
| | 8. | | Shared Dispositive Power 5,241,3782 | |||
| 9. | Aggregate Amount Beneficially Owned by Each Reporting Person 5,241,3782 | |||||
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨ | |||||
| 11. | Percent of Class Represented by Amount in Row (9) 7.1%3 | |||||
| 12. | Type of Reporting Person (See Instructions) PN | |||||
| 1 | Venrock Healthcare Capital Partners, L.P., VHCP Co-Investment Holdings, LLC, Venrock Healthcare Capital Partners II, L.P., VHCP Co-Investment Holdings II, LLC, VHCP Management, LLC, VHCP Management II, LLC, Bong Koh and Anders Hove are members of a group for the purposes of this Schedule 13G. |
| 2 | Consists of 473,101 shares owned by Venrock Healthcare Capital Partners, L.P., 86,542 shares owned by VHCP Co-Investment Holdings, LLC, 3,331,104 shares owned by Venrock Healthcare Capital Partners II, L.P. and 1,350,631 shares owned by VHCP Co-Investment Holdings II, LLC. |
| 3 | This percentage is calculated based upon 73,629,816 shares of the Issuer’s common stock outstanding as of January 31, 2016, as set forth in the Issuer’s annual report on Form 10-K filed with the Securities and Exchange Commission on February 26, 2016. |
Follow Biocryst Pharmaceuticals Inc (NASDAQ:BCRX)
Follow Biocryst Pharmaceuticals Inc (NASDAQ:BCRX)
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
Page 5 of 19 – SEC Filing
| CUSIP No. 09058V103 | Page 5 of 15 |
| 1. | Name of Reporting Persons VHCP Co-Investment Holdings II, LLC | |||||
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions) (a) x1 (b) ¨ | |||||
| 3. | SEC USE ONLY | |||||
| 4. | Citizenship or Place of Organization Delaware | |||||
| Number of Shares Beneficially Owned by Each Reporting Person With: | | 5. | | Sole Voting Power 0 | ||
| | 6. | | Shared Voting Power 5,241,3782 | |||
| | 7. | | Sole Dispositive Power 0 | |||
| | 8. | | Shared Dispositive Power 5,241,3782 | |||
| 9. | Aggregate Amount Beneficially Owned by Each Reporting Person 5,241,3782 | |||||
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨ | |||||
| 11. | Percent of Class Represented by Amount in Row (9) 7.1%3 | |||||
| 12. | Type of Reporting Person (See Instructions) OO | |||||
| 1 | Venrock Healthcare Capital Partners, L.P., VHCP Co-Investment Holdings, LLC, Venrock Healthcare Capital Partners II, L.P., VHCP Co-Investment Holdings II, LLC, VHCP Management, LLC, VHCP Management II, LLC, Bong Koh and Anders Hove are members of a group for the purposes of this Schedule 13G. |
| 2 | Consists of 473,101 shares owned by Venrock Healthcare Capital Partners, L.P., 86,542 shares owned by VHCP Co-Investment Holdings, LLC, 3,331,104 shares owned by Venrock Healthcare Capital Partners II, L.P. and 1,350,631 shares owned by VHCP Co-Investment Holdings II, LLC. |
| 3 | This percentage is calculated based upon 73,629,816 shares of the Issuer’s common stock outstanding as of January 31, 2016, as set forth in the Issuer’s annual report on Form 10-K filed with the Securities and Exchange Commission on February 26, 2016. |
Follow Biocryst Pharmaceuticals Inc (NASDAQ:BCRX)
Follow Biocryst Pharmaceuticals Inc (NASDAQ:BCRX)
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
Page 6 of 19 – SEC Filing
| CUSIP No. 09058V103 | Page 6 of 15 |
| 1. | Name of Reporting Persons VHCP Management, LLC | |||||
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions) (a) x1 (b) ¨ | |||||
| 3. | SEC USE ONLY | |||||
| 4. | Citizenship or Place of Organization Delaware | |||||
| Number of Shares Beneficially Owned by Each Reporting Person With: | | 5. | | Sole Voting Power 0 | ||
| | 6. | | Shared Voting Power 5,241,3782 | |||
| | 7. | | Sole Dispositive Power 0 | |||
| | 8. | | Shared Dispositive Power 5,241,3782 | |||
| 9. | Aggregate Amount Beneficially Owned by Each Reporting Person 5,241,3782 | |||||
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨ | |||||
| 11. | Percent of Class Represented by Amount in Row (9) 7.13 | |||||
| 12. | Type of Reporting Person (See Instructions) OO | |||||
| 1 | Venrock Healthcare Capital Partners, L.P., VHCP Co-Investment Holdings, LLC, Venrock Healthcare Capital Partners II, L.P., VHCP Co-Investment Holdings II, LLC, VHCP Management, LLC, VHCP Management II, LLC, Bong Koh and Anders Hove are members of a group for the purposes of this Schedule 13G. |
| 2 | Consists of 473,101shares owned by Venrock Healthcare Capital Partners, L.P., 86,542 shares owned by VHCP Co-Investment Holdings, LLC, 3,331,104 shares owned by Venrock Healthcare Capital Partners II, L.P. and 1,350,631 shares owned by VHCP Co-Investment Holdings II, LLC. |
| 3 | This percentage is calculated based upon 73,629,816 shares of the Issuer’s common stock outstanding as of January 31, 2016, as set forth in the Issuer’s annual report on Form 10-K filed with the Securities and Exchange Commission on February 26, 2016. |
Follow Biocryst Pharmaceuticals Inc (NASDAQ:BCRX)
Follow Biocryst Pharmaceuticals Inc (NASDAQ:BCRX)
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
Page 7 of 19 – SEC Filing
| CUSIP No. 09058V103 | Page 7 of 15 |
| 1. | Name of Reporting Persons VHCP Management II, LLC | |||||
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions) (a) x1 (b) ¨ | |||||
| 3. | SEC USE ONLY | |||||
| 4. | Citizenship or Place of Organization Delaware | |||||
| Number of Shares Beneficially Owned by Each Reporting Person With: | | 5. | | Sole Voting Power 0 | ||
| | 6. | | Shared Voting Power 5,241,3782 | |||
| | 7. | | Sole Dispositive Power 0 | |||
| | 8. | | Shared Dispositive Power 5,241,3782 | |||
| 9. | Aggregate Amount Beneficially Owned by Each Reporting Person 5,241,3782 | |||||
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨ | |||||
| 11. | Percent of Class Represented by Amount in Row (9) 7.1%3 | |||||
| 12. | Type of Reporting Person (See Instructions) OO | |||||
| 1 | Venrock Healthcare Capital Partners, L.P., VHCP Co-Investment Holdings, LLC, Venrock Healthcare Capital Partners II, L.P., VHCP Co-Investment Holdings II, LLC, VHCP Management, LLC, VHCP Management II, LLC, Bong Koh and Anders Hove are members of a group for the purposes of this Schedule 13G. |
| 2 | Consists of 473,101 shares owned by Venrock Healthcare Capital Partners, L.P., 86,542 shares owned by VHCP Co-Investment Holdings, LLC, 3,331,104 shares owned by Venrock Healthcare Capital Partners II, L.P. and 1,350,631 shares owned by VHCP Co-Investment Holdings II, LLC. |
| 3 | This percentage is calculated based upon 73,629,816 shares of the Issuer’s common stock outstanding as of January 31, 2016, as set forth in the Issuer’s annual report on Form 10-K filed with the Securities and Exchange Commission on February 26, 2016. |
Follow Biocryst Pharmaceuticals Inc (NASDAQ:BCRX)
Follow Biocryst Pharmaceuticals Inc (NASDAQ:BCRX)
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
Page 8 of 19 – SEC Filing
| CUSIP No. 09058V103 | Page 8 of 15 |
| 1. | Name of Reporting Persons Hove, Anders | |||||
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions) (a) x1 (b) ¨ | |||||
| 3. | SEC USE ONLY | |||||
| 4. | Citizenship or Place of Organization United States | |||||
| Number of Shares Beneficially Owned by Each Reporting Person With: | | 5. | | Sole Voting Power 0 | ||
| | 6. | | Shared Voting Power 5,241,3782 | |||
| | 7. | | Sole Dispositive Power 0 | |||
| | 8. | | Shared Dispositive Power 5,241,3782 | |||
| 9. | Aggregate Amount Beneficially Owned by Each Reporting Person 5,241,3782 | |||||
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨ | |||||
| 11. | Percent of Class Represented by Amount in Row (9) 7.1%3 | |||||
| 12. | Type of Reporting Person (See Instructions) IN | |||||
| 1 | Venrock Healthcare Capital Partners, L.P., VHCP Co-Investment Holdings, LLC, Venrock Healthcare Capital Partners II, L.P., VHCP Co-Investment Holdings II, LLC, VHCP Management, LLC, VHCP Management II, LLC, Bong Koh and Anders Hove are members of a group for the purposes of this Schedule 13G. |
| 2 | Consists of 473,101 shares owned by Venrock Healthcare Capital Partners, L.P., 86,542 shares owned by VHCP Co-Investment Holdings, LLC, 3,331,104 shares owned by Venrock Healthcare Capital Partners II, L.P. and 1,350,631 shares owned by VHCP Co-Investment Holdings II, LLC. |
| 3 | This percentage is calculated based upon 73,629,816 shares of the Issuer’s common stock outstanding as of January 31, 2016, as set forth in the Issuer’s annual report on Form 10-K filed with the Securities and Exchange Commission on February 26, 2016. |
Follow Biocryst Pharmaceuticals Inc (NASDAQ:BCRX)
Follow Biocryst Pharmaceuticals Inc (NASDAQ:BCRX)
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
Page 9 of 19 – SEC Filing
| CUSIP No. 09058V103 | Page 9 of 15 |
| 1. | Name of Reporting Persons Koh, Bong | |||||
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions) (a) x1 (b) ¨ | |||||
| 3. | SEC USE ONLY | |||||
| 4. | Citizenship or Place of Organization United States | |||||
| Number of Shares Beneficially Owned by Each Reporting Person With: | | 5. | | Sole Voting Power 0 | ||
| | 6. | | Shared Voting Power 5,241,3782 | |||
| | 7. | | Sole Dispositive Power 0 | |||
| | 8. | | Shared Dispositive Power 5,241,3782 | |||
| 9. | Aggregate Amount Beneficially Owned by Each Reporting Person 5,241,3782 | |||||
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨ | |||||
| 11. | Percent of Class Represented by Amount in Row (9) 7.1%3 | |||||
| 12. | Type of Reporting Person (See Instructions) IN | |||||
| 1 | Venrock Healthcare Capital Partners, L.P., VHCP Co-Investment Holdings, LLC, Venrock Healthcare Capital Partners II, L.P., VHCP Co-Investment Holdings II, LLC, VHCP Management, LLC, VHCP Management II, LLC, Bong Koh and Anders Hove are members of a group for the purposes of this Schedule 13G. |
| 2 | Consists of 473,101 shares owned by Venrock Healthcare Capital Partners, L.P., 86,542 shares owned by VHCP Co-Investment Holdings, LLC, 3,331,104 shares owned by Venrock Healthcare Capital Partners II, L.P. and 1,350,631 shares owned by VHCP Co-Investment Holdings II, LLC. |
| 3 | This percentage is calculated based upon 73,629,816 shares of the Issuer’s common stock outstanding as of January 31, 2016, as set forth in the Issuer’s annual report on Form 10-K filed with the Securities and Exchange Commission on February 26, 2016. |
Follow Biocryst Pharmaceuticals Inc (NASDAQ:BCRX)
Follow Biocryst Pharmaceuticals Inc (NASDAQ:BCRX)
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
Page 10 of 19 – SEC Filing
| CUSIP No. 09058V103 | Page 10 of 15 |
Introductory Note: This Schedule 13G is filed on behalf of Venrock Healthcare Capital Partners, L.P., a limited partnership organized under the laws of the State of Delaware (“VHCP I”), VHCP Co-Investment Holdings, LLC, a limited liability company organized under the laws of the State of Delaware (“VHCP Co-Invest I”), Venrock Healthcare Capital Partners II, L.P., a limited partnership organized under the laws of the State of Delaware (“VHCP II”), VHCP Co-Investment Holdings II, LLC, a limited liability company organized under the laws of the State of Delaware (“VHCP Co-Invest II”), VHCP Management, LLC, a limited liability company organized under the laws of the State of Delaware (“VHCP Management”), VHCP Management II, LLC, a limited liability company organized under the laws of the State of Delaware (“VHCP Management II” and collectively with VHCP I, VHCP Co-Invest I, VHCP II, VHCP Co-Investment II, and VHCP Management, the “Venrock Entities”), Anders Hove (“Hove”) and Bong Koh (“Koh”) in respect of Common Stock of BioCryst Pharmaceuticals, Inc.
| Item 1. |
| (a) | Name of Issuer |
BioCryst Pharmaceuticals, Inc.
| (b) | Address of Issuer’s Principal Executive Offices |
4505 Emperor Boulevard, Suite 200
Durham, NC 27703
| Item 2. |
| (a) | Name of Person Filing | |
| Venrock Healthcare Capital Partners, L.P. | ||
| VHCP Co-Investment Holdings, LLC | ||
| Venrock Healthcare Capital Partners II, L.P. | ||
| VHCP Co-Investment Holdings II, LLC | ||
| VHCP Management, LLC | ||
| VHCP Management II, LLC | ||
| Anders Hove | ||
| Bong Koh |
| (b) | Address of Principal Business Office or, if none, Residence |
| New York Office: | | Palo Alto Office: | | Boston Office: |
| 530 Fifth Avenue | | 3340 Hillview Avenue | | 470 Atlantic Avenue |
| 22nd Floor | | Palo Alto, CA 94304 | | 4th Floor |
| New York, NY 10036 | | | Boston, MA 02210 |
| (c) | Citizenship |
All entities were organized in Delaware. The individuals are both United States citizens.
Follow Biocryst Pharmaceuticals Inc (NASDAQ:BCRX)
Follow Biocryst Pharmaceuticals Inc (NASDAQ:BCRX)
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
Page 11 of 19 – SEC Filing
| CUSIP No. 09058V103 | Page 11 of 15 |
| (d) | Title of Class of Securities |
Common Stock, $0.01 par value
| (e) | CUSIP Number |
09058V103
| Item 3. | If this statement is filed pursuant to §§240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a: |
Not applicable
| Item 4. | Ownership |
| (a) | Amount Beneficially Owned as of March 28, 2016: | ||
| Venrock Healthcare Capital Partners, L.P. | 5,241,378(1) | ||
| VHCP Co-Investment Holdings, LLC | 5,241,378(1) | ||
| Venrock Healthcare Capital Partners II, L.P. | 5,241,378(1) | ||
| VHCP Co-Investment Holdings II, LLC | 5,241,378(1) | ||
| VHCP Management, LLC | 5,241,378(1) | ||
| VHCP Management II, LLC | 5,241,378(1) | ||
| Anders Hove | 5,241,378(1) | ||
| Bong Koh | 5,241,378(1) |
| (b) | Percent of Class as of March 28, 2016: | ||
| Venrock Healthcare Capital Partners, L.P. | 7.1% (2) | ||
| VHCP Co-Investment Holdings, LLC | 7.1% (2) | ||
| Venrock Healthcare Capital Partners II, L.P. | 7.1% (2) | ||
| VHCP Co-Investment Holdings II, LLC | 7.1% (2) | ||
| VHCP Management, LLC | 7.1% (2) | ||
| VHCP Management II, LLC | 7.1% (2) | ||
| Anders Hove | 7.1% (2) | ||
| Bong Koh | 7.1% (2) |
| (c) | Number of shares as to which the person has, as of March 28, 2016: | ||
| (i) | Sole power to vote or to direct the vote |
| Venrock Healthcare Capital Partners, L.P. | 0 | ||
| VHCP Co-Investment Holdings, LLC | 0 | ||
| Venrock Healthcare Capital Partners II, L.P. | 0 | ||
| VHCP Co-Investment Holdings II, LLC | 0 | ||
| VHCP Management, LLC | 0 | ||
| VHCP Management II, LLC | 0 | ||
| Anders Hove | 0 | ||
| Bong Koh | 0 |
Follow Biocryst Pharmaceuticals Inc (NASDAQ:BCRX)
Follow Biocryst Pharmaceuticals Inc (NASDAQ:BCRX)
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
Page 12 of 19 – SEC Filing
| CUSIP No. 09058V103 | Page 12 of 15 |
| (ii) | Shared power to vote or to direct the vote | ||
| Venrock Healthcare Capital Partners, L.P. | 5,241,378(1) | ||
| VHCP Co-Investment Holdings, LLC | 5,241,378(1) | ||
| Venrock Healthcare Capital Partners II, L.P. | 5,241,378(1) | ||
| VHCP Co-Investment Holdings II, LLC | 5,241,378(1) | ||
| VHCP Management, LLC | 5,241,378(1) | ||
| VHCP Management II, LLC | 5,241,378(1) | ||
| Anders Hove | 5,241,378(1) | ||
| Bong Koh | 5,241,378(1) |
| (V) | Sole power to dispose or to direct the disposition of | ||
| Venrock Healthcare Capital Partners, L.P. | 0 | ||
| VHCP Co-Investment Holdings, LLC | 0 | ||
| Venrock Healthcare Capital Partners II, L.P. | 0 | ||
| VHCP Co-Investment Holdings II, LLC | 0 | ||
| VHCP Management, LLC | 0 | ||
| VHCP Management II, LLC | 0 | ||
| Anders Hove | 0 | ||
| Bong Koh | 0 |
| (iv) | Shared power to dispose or to direct the disposition of | ||
| Venrock Healthcare Capital Partners, L.P. | 5,241,378(1) | ||
| VHCP Co-Investment Holdings, LLC | 5,241,378(1) | ||
| Venrock Healthcare Capital Partners II, L.P. | 5,241,378(1) | ||
| VHCP Co-Investment Holdings II, LLC | 5,241,378(1) | ||
| VHCP Management, LLC | 5,241,378(1) | ||
| VHCP Management II, LLC | 5,241,378(1) | ||
| Anders Hove | 5,241,378(1) | ||
| Bong Koh | 5,241,378(1) |
| (1) | These shares are owned directly as follows: 473,101 shares are owned by VHCP I, 86,542 shares are owned by VHCP Co-Invest I, 3,331,104 shares are owned by VHCP II and 1,350,631 shares are owned by VHCP Co-Invest II. | |
| (2) | This percentage is calculated based upon 73,629,816 shares of the Issuer’s common stock outstanding as of January 31, 2016, as set forth in the Issuer’s annual report on Form 10-K filed with the Securities and Exchange Commission on February 26, 2016. | |
| Item 5. | Ownership of Five Percent or Less of a Class | |
If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following o.
| Item 6. | Ownership of More than Five Percent on Behalf of Another Person |
Not Applicable
Follow Biocryst Pharmaceuticals Inc (NASDAQ:BCRX)
Follow Biocryst Pharmaceuticals Inc (NASDAQ:BCRX)
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
Page 13 of 19 – SEC Filing
| CUSIP No. 09058V103 | Page 13 of 15 |
| Item 7. | Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person. |
Not Applicable
| Item 8. | Identification and Classification of Members of the Group |
Not Applicable
| Item 9. | Notice of Dissolution of a Group |
Not Applicable
| Item 10. | Certification |
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.
Follow Biocryst Pharmaceuticals Inc (NASDAQ:BCRX)
Follow Biocryst Pharmaceuticals Inc (NASDAQ:BCRX)
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
Page 14 of 19 – SEC Filing
| CUSIP No. 09058V103 | Page 14 of 15 |
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this Statement is true, complete and correct.
Dated: March 28, 2016
| Venrock Healthcare Capital Partners, L.P. | VHCP Co-Investment Holdings, LLC | |||||||||||
| By: | VHCP Management, LLC, | By: | VHCP Management, LLC, | |||||||||
| its General Partner | its Manager | |||||||||||
| By: | /s/ David L. Stepp | By: | /s/ David L. Stepp | |||||||||
| Name: | David L. Stepp | Name: | David L. Stepp | |||||||||
| Title: | Authorized Signatory | Title: | Authorized Signatory | |||||||||
| VHCP Management, LLC | ||||||||||||
| By: | /s/ David L. Stepp | |||||||||||
| Name: | David L. Stepp | |||||||||||
| Title: | Authorized Signatory | |||||||||||
| /s/ David L. Stepp, as attorney-in-fact | ||||||||||||
| Anders Hove | ||||||||||||
| /s/ David L. Stepp, as attorney-in-fact | ||||||||||||
| Bong Koh | ||||||||||||
| Venrock Healthcare Capital Partners II, L.P. | VHCP Co-Investment Holdings II, LLC | |||||||||||
| By: | VHCP Management II, LLC, | By: | VHCP Management II, LLC, | |||||||||
| its General Partner | its Manager | |||||||||||
| By: | /s/ David L. Stepp | By: | /s/ David L. Stepp | |||||||||
| Name: | David L. Stepp | Name: | David L. Stepp | |||||||||
| Title: | Authorized Signatory | Title: | Authorized Signatory | |||||||||
| VHCP Management II, LLC | ||||||||||||
| By: | /s/ David L. Stepp | |||||||||||
| Name: | David L. Stepp | |||||||||||
| Title: | Authorized Signatory | |||||||||||
Follow Biocryst Pharmaceuticals Inc (NASDAQ:BCRX)
Follow Biocryst Pharmaceuticals Inc (NASDAQ:BCRX)
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
Page 15 of 19 – SEC Filing
| CUSIP No. 09058V103 | Page 15 of 15 |
EXHIBITS
| A: | Joint Filing Agreement |
| B: | Power of Attorney for Anders Hove |
| C: | Power of Attorney for Bong Koh |
Follow Biocryst Pharmaceuticals Inc (NASDAQ:BCRX)
Follow Biocryst Pharmaceuticals Inc (NASDAQ:BCRX)
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
Page 16 of 19 – SEC Filing
EXHIBIT A
JOINT FILING AGREEMENT
In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the Common Stock of BioCryst Pharmaceuticals, Inc. and further agree that this agreement be included as an exhibit to such filing. Each party to the agreement expressly authorizes each other party to file on its behalf any and all amendments to such statement. Each party to this agreement agrees that this joint filing agreement may be signed in counterparts.
In evidence whereof, the undersigned have caused this Agreement to be executed on their behalf this 28th day of March, 2016.
| Venrock Healthcare Capital Partners, L.P. | ||
| By: VHCP Management, LLC | ||
| Its: General Partner | ||
| By: | /s/ David L. Stepp | |
| David L. Stepp | ||
| Authorized Signatory | ||
| VHCP Co-Investment Holdings, LLC | ||
| By: VHCP Management, LLC | ||
| Its: Manager | ||
| By: | /s/ David L. Stepp | |
| David L. Stepp | ||
| Authorized Signatory | ||
| VHCP Management, LLC | ||
| By: | /s/ David L. Stepp | |
| David L. Stepp | ||
| Authorized Signatory | ||
| Venrock Healthcare Capital Partners II, L.P. | ||
| By: VHCP Management II, LLC | ||
| Its: General Partner | ||
| By: | /s/ David L. Stepp | |
| David L. Stepp | ||
| Authorized Signatory | ||
| VHCP Co-Investment Holdings II, LLC | ||
| By: VHCP Management II, LLC | ||
| Its: Manager | ||
| By: | /s/ David L. Stepp | |
| David L. Stepp | ||
| Authorized Signatory | ||
| VHCP Management II, LLC | ||
| By: | /s/ David L. Stepp | |
| David L. Stepp | ||
| Authorized Signatory | ||
Follow Biocryst Pharmaceuticals Inc (NASDAQ:BCRX)
Follow Biocryst Pharmaceuticals Inc (NASDAQ:BCRX)
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
Page 17 of 19 – SEC Filing
| /s/ David L. Stepp, as attorney-in-fact |
| Anders Hove |
| /s/ David L. Stepp, as attorney-in-fact |
| Bong Koh |
Follow Biocryst Pharmaceuticals Inc (NASDAQ:BCRX)
Follow Biocryst Pharmaceuticals Inc (NASDAQ:BCRX)
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
Page 18 of 19 – SEC Filing
EXHIBIT B
POWER OF ATTORNEY FOR ANDERS HOVE
KNOW ALL BY THESE PRESENTS, that the undersigned hereby constitutes and appoints each of David L. Stepp, Mark G. Thompson, and Dick Bradshaw, signing individually, the undersigned’s true and lawful attorney-in fact and agent to:
| (i) | prepare execute and file, for and on behalf of the undersigned, any and all documents and filings that are required or advisable to be made with the United States Securities and Exchange Commission, any stock exchange or similar authority, under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and the rules and regulations promulgated thereunder, including without limitation (a) any Joint Filing Agreement under Rule 13d-1(k) of the Exchange Act (or any successor provision thereunder), Schedule 13D and Schedule 13G (or any successor schedules or forms adopted under the Exchange Act ) and any amendments thereto in accordance with Section 13 of the Exchange Act and the rules thereunder, and (b) Forms 3, 4 and 5 and any amendments thereto in accordance with Section 16(a) of the Exchange Act and the rules thereunder; and |
| (ii) | take any other action of any nature whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact’s discretion. |
The undersigned hereby grants to such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact’s substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorney-in-fact, in serving in such capacity at the request of undersigned, is not assuming, nor is Venrock assuming, any of the undersigned’s responsibilities to comply with the Exchange Act, including without limitation Sections 13 and 16 of the Exchange Act.
This power of Attorney shall remain in full force and effect until the earliest to occur of (a) the undersigned is no longer required to file any form or document with respect to the undersigned’s holdings of and transactions in securities issued by a company, (b) revocation by the undersigned in a signed writing delivered to the foregoing attorney-in-fact, or (c) until such attorney-in-fact shall no longer be employed by VR Management, LLC (or its successor).
IN WITNESS WHEREOF, the undersigned has cause this Power of Attorney to be executed as of this 4th day of January, 2010.
| /s/ Anders Hove |
Follow Biocryst Pharmaceuticals Inc (NASDAQ:BCRX)
Follow Biocryst Pharmaceuticals Inc (NASDAQ:BCRX)
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
Page 19 of 19 – SEC Filing
EXHIBIT C
POWER OF ATTORNEY FOR BONG KOH
KNOW ALL BY THESE PRESENTS, that the undersigned hereby constitutes and appoints each of Lisa Harris, Sherman G. Souther, Jr. and David L. Stepp, signing individually, the undersigned’s true and lawful attorney-in fact and agent to:
| (i) | prepare, execute and file, for and on behalf of the undersigned, any and all documents and filings that are required or advisable to be made with the United States Securities and Exchange Commission, any stock exchange or similar authority, under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and the rules and regulations promulgated thereunder, including without limitation (a) any Joint Filing Agreement under Rule 13d-1(k) of the Exchange Act (or any successor provision thereunder), Schedule 13D and Schedule 13G (or any successor schedules or forms adopted under the Exchange Act) and any amendments thereto in accordance with Section 13 of the Exchange Act and the rules thereunder, and (b) Forms 3, 4 and 5 and any amendments thereto in accordance with Section 16(a) of the Exchange Act and the rules thereunder; and |
| (ii) | take any other action of any nature whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact’s discretion. |
The undersigned hereby grants to such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact’s substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorney-in-fact, in serving in such capacity at the request of the undersigned, is not assuming, nor is Venrock assuming, any of the undersigned’s responsibilities to comply with the Exchange Act, including without limitation Sections 13 and 16 of the Exchange Act.
This Power of Attorney shall remain in full force and effect until the earliest to occur of (a) the undersigned is no longer required to file any form or document with respect to the undersigned’s holdings of and transactions in securities issued by a company, (b) revocation by the undersigned in a signed writing delivered to the foregoing attorney-in-fact or (c) until such attorney-in-fact shall no longer be employed by Venrock.
IN WITNESS WHEREOF, the undersigned has cause this Power of Attorney to be executed as of this 26th day of January, 2015.
| /s/ Bong Koh |
| Bong Koh |
Follow Biocryst Pharmaceuticals Inc (NASDAQ:BCRX)
Follow Biocryst Pharmaceuticals Inc (NASDAQ:BCRX)
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
